PURPOSE: A simple stability indicating reverse phase liquid chromatographic method was developed for the simultaneous determination of rosuvastatin and ezetimibe in pharmaceutical formulations. METHODS: Best chromatographic response was achieved with C18 column (250 X 4.6 mm, 5µm) with photo diode array (PDA) detector. The mobile phase was composed of a mixture of sodium acetate buffer (pH 4.0) and acetonitrile (30:70, %v/v) with a flow rate of 1.2 mL/min. (UV detection at 254 nm). Rosuvastatin and ezetimibe were subjected to stress conditions of degradation and the method was validated as per ICH guidelines. RESULTS: The method shows linearity over a concentration range of 0.5-250 µg/ml for both rosuvastatin (r2 = 0.9993) and ezetimibe (r2 = 0.9996). Both the drugs are highly sensitive towards alkaline conditions in comparison to other stress conditions. CONCLUSION: The proposed method can be successfully applied to perform long-term and accelerated stability studies for the simultaneous determination of rosuvastatin and ezetimibe in pharmaceutical formulations.
PURPOSE: A simple stability indicating reverse phase liquid chromatographic method was developed for the simultaneous determination of rosuvastatin and ezetimibe in pharmaceutical formulations. METHODS: Best chromatographic response was achieved with C18 column (250 X 4.6 mm, 5µm) with photo diode array (PDA) detector. The mobile phase was composed of a mixture of sodium acetate buffer (pH 4.0) and acetonitrile (30:70, %v/v) with a flow rate of 1.2 mL/min. (UV detection at 254 nm). Rosuvastatin and ezetimibe were subjected to stress conditions of degradation and the method was validated as per ICH guidelines. RESULTS: The method shows linearity over a concentration range of 0.5-250 µg/ml for both rosuvastatin (r2 = 0.9993) and ezetimibe (r2 = 0.9996). Both the drugs are highly sensitive towards alkaline conditions in comparison to other stress conditions. CONCLUSION: The proposed method can be successfully applied to perform long-term and accelerated stability studies for the simultaneous determination of rosuvastatin and ezetimibe in pharmaceutical formulations.
Entities:
Keywords:
Ezetimibe; ICH guidelines; Isocratic; RP-HPLC; Rosuvastatin
Authors: A Mohammadi; N Rezanour; M Ansari Dogaheh; F Ghorbani Bidkorbeh; M Hashem; R B Walker Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2006-09-28 Impact factor: 3.205
Authors: F McTaggart; L Buckett; R Davidson; G Holdgate; A McCormick; D Schneck; G Smith; M Warwick Journal: Am J Cardiol Date: 2001-03-08 Impact factor: 2.778
Authors: Teddy Kosoglou; Paul Statkevich; Amy O Johnson-Levonas; John F Paolini; Arthur J Bergman; Kevin B Alton Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447
Authors: M Van Heek; C F France; D S Compton; R L McLeod; N P Yumibe; K B Alton; E J Sybertz; H R Davis Journal: J Pharmacol Exp Ther Date: 1997-10 Impact factor: 4.030